Publications
- Jirathitikal V, Bourinbaiar AS. Safety and efficacy of an oral HIV vaccine (V-1 Immunitor) in AIDS patients at various stages of the disease. HIV Clin Trials 2002; 3:21-26. http://www.ncbi.nlm.nih.gov/pubmed/11819182
- Sooksathan P, Metadilogkul O, Bourinbaiar AS. V-1 Immunitor: Oral AIDS vaccine with therapeutic and prophylactic potential. Vaccine 2003, 21:624-628. http://www.ncbi.nlm.nih.gov/pubmed/12531330
- Bourinbaiar AS, Metadilogkul O, Jirathitikal V. Mucosal AIDS vaccines. Viral Immunol 2003;16:427-445. http://www.ncbi.nlm.nih.gov/pubmed/14733732
- Jirathitikal V, Bourinbaiar AS. Effect of an oral therapeutic HIV-1 vaccine on AIDS patients with CD4 count above 250 cells/mm³. Acta Virologica 2004; 48: 73-78. http://www.ncbi.nlm.nih.gov/pubmed/15462281
- Bourinbaiar AS, Jirathitikal V, Metadilogkul O, Sooksathan P, Aemsri S, Promdevich P, Paiboon P, Chaodon K. Phase II placebo-controlled study of V-1 Immunitor as a therapeutic modality for treatment of HIV. J Clin Virol 2004; 31:S55-S62. http://www.ncbi.nlm.nih.gov/pubmed/15567095
- Bourinbaiar AS and Abulafia-Lapid R. Clinical experience with therapeutic AIDS vaccines. Expert Rev Vaccines 2005;4:289-304. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2224394/
- Bourinbaiar AS and Abulafia-Lapid R. Autoimmunity, alloimmunization, and immunotherapy of AIDS. Autoimmunity Reviews 2005; 4:403-409. http://www.ncbi.nlm.nih.gov/pubmed/16081032
- Metadilogkul O, Jirathitikal V, Bourinbaiar AS. Prolonged survival of end-stage AIDS patients immunized with therapeutic HIV vaccine V-1 Immunitor. Biomed & Pharmacother 2005;59: 469-473. http://www.ncbi.nlm.nih.gov/pubmed/16126364
- Jirathitikal V, Metadilogkul O, Bourinbaiar AS. Increased body weight and improved quality of life in AIDS patients following V-1 Immunitor administration. Eur J Clin Nutr 2004;58:110-115. http://www.ncbi.nlm.nih.gov/pubmed/14679375
- Jirathitikal V, Metadilogkul O, Bourinbaiar AS. Preclinical and safety studies of V-1 Immunitor. Int J Biotechnol 2007;9:318-331. http://www.ingentaconnect.com/content/ind/ijbt/2007/00000009/
- Bourinbaiar AS, Root-Bernstein R, Abulafia-Lapid R, Rytik P, Jirathitikal V, Kanev AN, Orlovsky VG, Therapeutic AIDS vaccines. Curr Pharm Design 2006;12: 2017-2030. http://www.ncbi.nlm.nih.gov/pubmed/16787245
- Bourinbaiar AS, Jirathitikal V, Silin DS, Lu N-Q, Abulafia-Lapid R. AIDS vaccines and reproductive immunology. Current Immunol Rev 2007;3:101-107. http://www.ingentaconnect.com/content/ben/cir/2007/00000003/
- Silin DS, Lyubomska OV, Jirathitikal V, Bourinbaiar AS. Oral vaccination: where we are? Expert Opinion Drug Delivery 2007:4;1-18. http://www.ncbi.nlm.nih.gov/pubmed/17683247
- Jirathitikal V, Bourinbaiar AS. Serodeconversion of HIV antibody-positive patients following treatment with V-1 Immunitor. J Biomed Biotech 2009:934579. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2577775/
- Bourinbaiar A, Orlovsky V, Jirathitikal V, Metadilogkul O, Popov D. Pilot trial of oral therapeutic HIV vaccine, V-1 Immunitor, on HIV and HIV/HCV patients in Russia. Retrovirology 2010;7(Suppl 1):P30. http://www.retrovirology.com/content/pdf/1742-4690-7-S1-P30.pdf
- Jirathitikal V, Metadilogkul O, Bourinbaiar AS. Normalization of elevated liver enzymes due to V-1 Immunitor therapy. Electr J Biotechnol 2003; 6:76-79. http://www.ejbiotechnology.info/content/vol6/issue1/full/3/index.html
- Batdelger D, Dandii D, Jirathitikal V, Bourinbaiar AS. Open label trial of therapeutic hepatitis B vaccine V-5 Immunitor (V5) delivered by oral route. Lett Drug Design Discovery 2007;4:540-44. http://www.ingentaconnect.com/content/ben/lddd/2007/00000004/
- Batdelger D, Dandii D, Jirathitikal V, Bourinbaiar AS. Open label trial of therapeutic immunization with oral V-5 Immunitor (V5) vaccine in patients with chronic hepatitis C. Vaccine 2008;26:2733-2737.127. http://www.ncbi.nlm.nih.gov/pubmed/18455842
- Batdelger D, Dandii D, Dahgwahdorj Ya, Erdenetsogt E, Oyunbileg J, Tsend N, Bayarmagnai B, Jirathitikal V, Bourinbaiar AS. Clinical experience with therapeutic vaccines designed for patients with hepatitis. Curr Pharm Design 2009;15:1159-1171. http://www.ncbi.nlm.nih.gov/pubmed/19355957
- Bourinbaiar AS, Jirathitikal V. Safety and efficacy trial of adipose-tissue derived oral preparation V-6 Immunitor (V-6): results of open-label, two-month, follow-up study. Lipids Health Dis 2010;9:14. http://www.ncbi.nlm.nih.gov/pubmed/20122177
- Bourinbaiar AS, Jirathitikal V. Effect of oral immunization with pooled antigens derived from adipose tissue on atherosclerosis and obesity indices. Vaccine 2010;28:2763-8. http://www.ncbi.nlm.nih.gov/pubmed/20117273
- Bourinbaiar AS, Orlovsky V, Jirathitikal V. Preliminary evidence of safety and efficacy of an orally administered, heat-inactivated H5N1 influenza vaccine. Proc Vaccinol 2010;2:60-65. doi:10.1016/j.provac.2010.03.011
- Arjanova OV, Prihoda ND, Yurchenko LV, Sokolenko NI, Frolov VM, Tarakanovskaya MG, Jirathitikal V, Bourinbaiar AS. Phase 2 trial of V-5 Immunitor (V5) in patients with chronic hepatitis C co-infected with HIV and Mycobacterium tuberculosis. J Vaccines Vaccination 2010;1:103 http://omicsonline.org/2157-7560/2157-7560-1-103.php